
Wegovy (semaglutide 2.4 mg) available in New Zealand for weight loss and cardiovascular risk reduction from July 1
Wegovy (semaglutide 2.4mg), the first once-weekly GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and adolescents age 12 years and above, will be available in …